Xconomy

JUNE 1, 2018

In setting a price thousands of dollars less than expected, Amgen has won over one of the pharmaceutical industry’s fiercest drug price critics. As Amgen approached an FDA decision last month for its migraine-prevention treatment , concern mounted that the drug would come at premium. After the FDA approved erenumab last.

Pricing 75

Pricing Report San Diego Blogging 75

Xconomy

AUGUST 11, 2020

The larger company agreed to pay $12 per share for Pfenex (NYSE American: PFNX )—a 57 percent premium to its closing price Monday. San Diego-based Ligand (NASDAQ: LGND ) generates revenue from licensing deals and royalties paid by pharmaceutical companies that use technologies it develops or acquires for their own drug research.

San Diego 98

San Diego Technology Research Pricing 98

Xconomy

OCTOBER 19, 2018

Two new battlegrounds emerged this week in the nation’s ongoing drug pricing debate. The first involved television: The federal government hopes that blaring prices in TV ads will essentially pressure drug makers into lowering them, and the pharma lobby fired back.

Pricing 74

Pricing Class San Diego Venture Capital 74

Xconomy

JULY 2, 2018

A paper published last week in the journal JAMA Oncology makes the case that one such test, Oncotype DX AR-V7 Nucleus Detect, might be worth its $3,980 price tag. Earlier this year, the federal insurance program Medicare sent positive signals about coverage but hasn’t made a final decision.)

Guide 81

Guide Study San Diego Journal 81

Xconomy

DECEMBER 18, 2018

The venture investment, which the San Diego startup announced Tuesday, is one of only a few so-called mega-rounds—$100 million or more—recorded this year in the region. (In Thompson to its board of directors. In Southern California, rounds that large are more often raised by life sciences companies.)

Southern California 110

Southern California San Diego Software Invest 110

Xconomy

APRIL 26, 2019

The road to every new drug approval is littered with the remains of earlier failures. Biopharmaceutical companies don’t like to talk about the failures. But it’s earnings season now, so some of them don’t have much choice.

News 94

News Pricing Study Company 94

Xconomy

MARCH 10, 2017

The San Diego-based biotech filed the paperwork Thursday for an IPO that could raise up to $86 million—a figure likely to change as the company determines how many shares it will sell, and at what price. Tocagen has applied to the Nasdaq Exchange for a listing under the stock symbol “TOCA.”

San Diego 79

San Diego Pricing Southern California Develop 79

Xconomy

OCTOBER 6, 2016

Headed by the computational neuroscientist Eugene Izhikevich, the company maintained a low profile at Qualcomm’s San Diego headquarters until 2013, when Brain Corp. The company actually has been test-driving its technology on floor scrubbers used to clean Jimbo’s, a San Diego natural foods grocer. “We While Brain Corp.

Product 106

Product Artificial Inteligence San Diego Training 106

Xconomy

OCTOBER 24, 2018

Amgen is cutting the list price of its new cholesterol-lowering drug by nearly 60 percent, a move the company says is intended to make the product more affordable for more patients. The Tarrytown, NY firm recently offered significant price cuts to insurance companies that help boost access to its rival medicine alirocumab (Praluent).

Pricing 55

Pricing Help Product San Diego 55

Xconomy

APRIL 23, 2019

As public backlash against high drug prices shows no signs of waning, a private nonprofit in Boston, the Institute for Clinical Economic Review (ICER), has emerged as the country’s top drug-pricing watchdog. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 104

Pricing Report Funding San Diego 104

Xconomy

NOVEMBER 19, 2018

The San Diego-based biotech set a preliminary $100 million target for its IPO in documents filed with securities regulators Friday. That figure will change as the company determines how many shares it will sell and at what price. Cibus has applied for a listing on the Nasdaq exchange under the stock symbol “CBUS.”

San Diego 72

San Diego Research Startup Pricing 72

Xconomy

AUGUST 2, 2019

Investors, however, buoyed the company’s share price this week after Acadia (NASDAQ: ACAD ) announced it anticipated that sales of Nuplazid, its sole commercial drug, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 61

Pricing Sales Company Companies 61

Xconomy

AUGUST 30, 2017

Ahead of schedule, Novartis has received the first-ever approval of a genetically modified living cell therapy called CAR-T, which uses a cancer patient’s own immune cells as the medicine.

Pricing 81

Pricing Conference San Diego Research 81

Xconomy

JULY 14, 2017

Akcea Therapeutics is joining the parade of biotechs going public, but the company had to cut its stock price and sell more shares in order to pull it off. But the biotech priced its offering of 15.6 Cambridge, MA-based Akcea had planned on raising $125 million from the initial public offering, and it hit that target.

Pricing 57

Pricing Company Companies San Diego 57

Xconomy

JANUARY 31, 2020

million more shares than anticipated and pricing at the high end of its planned range. The stock price closed at $21.80, up 28 percent. Arcutis Biotherapeutics raised about $159 million from its IPO, offering 1.6 The Westlake Village, CA-based biotech sold about 9.4 million of its shares at $17 apiece.

Westlake Village 114

Westlake Village Pricing Develop Development 114

Xconomy

JULY 29, 2020

On Wednesday the Cambridge, MA-based company, which was launched last year by Third Rock Ventures, announced that New York investment firm Casdin Capital and San Diego area-based venture firm Section 32 had co-led its Series B. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 87

San Diego Study Capital Invest 87

Xconomy

APRIL 17, 2019

Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more shares into the public markets than it had initially planned. million shares at $18 apiece, raising $166.5 million before discounts, commissions, and offering expenses.

Pricing 57

Pricing Demand Marketing Develop 57

Xconomy

MAY 9, 2019

Five biotechs priced their IPOs and at least one more is coming. According to IPO research firm Renaissance Capital , 47 IPOs have priced so far this year across all sectors, down 27 percent compared to the same period in 2018. Just as last year, healthcare IPOs lead the way.

Pricing 110

Pricing Research Capital Marketing 110

Xconomy

MARCH 20, 2017

Japan’s Murata Manufacturing has acquired Arctic Sand Technologies of Burlington, MA, and plans to combine Arctic Sand’s low-power semiconductor technology with its San Diego-based subsidiary, Peregrine Semiconductor. The purchase price was $68 million, according to a Peregrine spokeswoman.

San Diego 63

San Diego Mobile Pricing Technology 63

Xconomy

MARCH 12, 2018

For 20 years, Deborah Long (pictured) has been relying on powerful drugs to keep her multiple sclerosis in check. Her out-of-pocket costs were pretty reasonable until two years ago, she says, when she had to switch insurance companies. Her new insurer made her switch to a different drug, Copaxone.

Pricing 71

Pricing San Diego Company Companies 71

Xconomy

DECEMBER 21, 2018

It’s beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather.

Pricing 73

Pricing Sales Study News 73

Xconomy

JANUARY 10, 2020

Signatories agreed to what they dubbed a New Commitment to Patients, a list of “core principals and actions” promising that “pricing of our medicines at launch will reflect innovation and value to patients” and “any price increases on our medicines must be reasonable and guided by the need for uninterrupted patient access.”

Pricing 52

Pricing Guide San Diego Company 52

Xconomy

AUGUST 15, 2019

Now the corporate venture arm of the global package delivery giant says it has taken a minority stake in the San Diego startup, which believes its technology can reduce the costs of shipping goods via tractor-trailer by 30 percent. Financial terms of the deal, announced Thursday, weren’t disclosed.

San Diego 79

San Diego Startup Technology Company 79

Xconomy

MAY 16, 2018

For some migraine sufferers, bright lights or loud sounds are enough to touch off an attack. For others, stress sparks the onset of pain. Bright lights, loud sounds, stress: Migraine triggers vary from one patient to another. But a common element is the abundance of a pain-inducing protein in the blood.

Pricing 77

Pricing Develop Development San Diego 77

Xconomy

OCTOBER 3, 2016

It’s the same performance at one-twentieth the price,” Morris says. His San Leandro, CA-based company, TerrAvion , relies on a network of contract pilots to capture weekly shots of his customers’ vineyards, corn fields, and strawberry rows. Morris says an equivalent coverage using drones would cost 20 times as much.

San Diego 107

San Diego Outsource Development Startup Resource 107

Xconomy

SEPTEMBER 17, 2020

Late Wednesday, Dyne priced its offering of about 12.3 Dyne Therapeutics, a company developing genetic medicines for rare muscular disorders, has raised $233 million in an IPO that topped the preclinical-stage biotech’s projections. million shares at $19 each. The Waltham, MA-based biotech had previously planned to sell 10.3

Pricing 114

Pricing Technology Develop Development 114

Xconomy

FEBRUARY 2, 2018

The San Diego-based early stage biotech, which specializes in RNA medicines, did not explain in a statement today why the Arcturus board decided to terminate Payne—only that his dismissal “is not related to Arcturus’ operational performance, ongoing programs, financial condition, or financial reporting.”

Arcturus 56

Arcturus San Diego Pricing Report 56

Xconomy

SEPTEMBER 13, 2017

Last week, the first genetically modified cell therapy came to market with a price tag of $475,000. The national debate over the high cost of healthcare, with prescription drugs at the center, resonates from the chambers of Congress to every American’s pocketbook. And it’s growing fiercer by the day.

Pricing 49

Pricing Marketing San Diego Blogging 49

Xconomy

DECEMBER 14, 2018

Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used insulin. But the university also allowed them to patent the improvements they made, which enabled them to slap higher prices on each new version. to offer competitive pricing pressure.

Patents 77

Patents Pricing Competition San Diego 77

Xconomy

MAY 24, 2019

But it comes with a cost: At $2.125 million, Zolgensma’s price tag creates a critical test for the economic viability of gene therapy as it goes head-to-head with an established treatment. The news marks a milestone for SMA patients, who have only one other approved medicine available.

News 107

News Pricing San Diego Blogging 107

Xconomy

JANUARY 11, 2017

The firm acknowledged price hikes on several drugs that stayed—sometimes barely—under the 10 percent limit that CEO Brent Saunders pledged last September, in what he called a “ social contract with patients.” The first test of pharmaceutical giant Allergan’s promise to behave responsibly came last week.

Pricing 40

Pricing .Net Conference Invest 40

Xconomy

AUGUST 25, 2017

This week saw some skirmishes in the drug price debate, new plans to expand the. Those of us who stepped outside with eclipse glasses, pin-hole projectors, or even colanders found a brief respite from the news. But developments in health policy and life sciences march onward. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 49

Pricing News Develop Development 49

Xconomy

JUNE 16, 2016

In San Diego, the complaints often focus on the relative scarcity of venture capital and hometown VC firms. So when the San Diego Venture Group recruited Mark Suster of Los Angeles-based Upfront Ventures to give the keynote talk Tuesday night for Startup Week San Diego, more than 800 people filled a downtown auditorium.

Venture Capital 49

Venture Capital San Diego Truecar Web 49

Xconomy

AUGUST 31, 2017

The no-charge promise didn’t assuage critics of the price. “While Novartis’ decision to set a price at $475,000 per treatment may be seen by some as restraint, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 79

Pricing Help Marketing Product 79

Xconomy

AUGUST 31, 2020

That price is a 60 percent premium to the Boston-based company’s closing stock price on Friday. The definitive agreement announced Monday calls for Carlsbad, CA-based Ionis (NASDAQ: IONS ) to pay $18.15 for each share of Akcea (NASDAQ: AKCA ) that it does not already own. Akcea develops drugs for rare diseases.

Pricing 89

Pricing Product Develop Development 89

Xconomy

FEBRUARY 4, 2019

Battery-technology business Maxwell Technologies has agreed to be acquired by Silicon Valley electric car company Tesla (NASDAQ: TSLA ) in an all-stock deal valued at about $218 million, the San Diego-based company announced Monday. apiece, a 55 percent premium over its stock price as of market close Feb.

Technology 46

Technology San Diego Pricing News 46

Xconomy

MAY 9, 2019

billion in new capital late Thursday as it priced an initial public offering that set its market capitalization at $82.4 That price is near the lowest end of the range Uber set at $44 to $50 in the amended prospectus it filed on April 26. Ride-hailing giant Uber secured $8.1

Marketing 88

Marketing Pricing News Capital 88